Decoy Therapeutics Inc. (DCOY)

NASDAQ: DCOY · USD

$1.09

+0.06 (+5.8%)· Recorded snapshot

Market cap	714.2K
Revenue (ttm)	227.6K
Net income (ttm)	-14.4M
EPS (ttm)	-$40.4
Shares out	655.2K
Volume	64,049
Beta	0.64

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 227.6K
Net income (ttm): -14.4M
EPS (ttm): -$40.4
Market cap: 714.2K

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-827.8

P25 -113.8P50 -46.5P75 -0.9

ROIC-218.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All DCOY indicators

Market & fundamental data

Available fields

186

Groups with data

Currency

USD

Showing 186 of 186 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001615219
Company name	Decoy Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	79400X602
Earnings date	2026-11-16
Earnings time	bmo
Employees	11
Employees change	9
Employees growth	450%
Enterprise value	$-7.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US79400X6022
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split date	2026-03-09
Last stock split type	Reverse
Market cap	$714,152
Market cap category	Nano-Cap
Next earnings date	2026-11-16
Options	No
Price	$1.09
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	DCOY
U.S. state	Texas
Website	https://decoytx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3,706.08%
FCF / EV yield	110.46%
FCF yield	-1,171.59%
P/B ratio	0.13x
P/S ratio	3.14x
Price / tangible book value	0.17x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-2,679.3%
Pretax margin	-6,347.85%
Profit per employee	$-1.3M
Revenue per employee	$20,694
ROA	-73.35%
ROA (5Y)	-52.59%
ROCE	-141.15%
ROE	-827.77%
ROE (5Y)	-166.61%
ROIC	-218.37%
SBC / revenue	255.5%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth years	0
Revenue growth 5Y	-45.41%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-42,424
Depreciation and amortization	$24,495
EBIT	$-6.1M
EBITDA	$-6.1M
EPS	$-40.40
FCF per share	$-12.77
Financing cash flow	$15.1M
Free cash flow	$-8.4M
Free cash flow minus SBC	$-8.9M
Gross profit	$-1.6M
Investing cash flow	$722,311
Net cash flow	$7.5M
Net income	$-14.4M
Operating cash flow minus SBC	$-8.9M
Operating income	$-6.1M
Revenue	$227,629
Stock-based compensation	$581,590

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-16.63
Book value per share	$8.12
Debt / equity	0
Long-term assets	$427,852
Long-term liabilities	$0
Net cash (debt)	$8.3M
Net cash / market cap	1,160.69%
Net cash growth	942.8%
Net debt / equity	-1.92
Piotroski F-Score	2
Property, plant and equipment	$399,077
Shareholders' equity	$4.3M
Tangible book value	$4.3M
Tangible book value per share	$8.12
Total assets	$9M
Total cash	$8.3M
Total debt	$0
Total liabilities	$4.7M
WACC	7.79%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.04
Current assets	$8.6M
Current liabilities	$4.7M
Current ratio	1.83
Net working capital	$-4.4M
Quick ratio	1.77
Working capital	$3.9M
Working capital turnover	0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-319.16%
Dividend yield	0%
Shareholder yield	-319.16%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.59
1D price change	5.83%
1M price change	-64.4%
1M total return	-64.4%
1W price change	-3.09%
1W total return	-3.09%
1Y price change	-97.61%
1Y return CAGR	-97.61%
1Y total return	-97.61%
20-day SMA	$1.31
200-day SMA	$5.63
3M price change	-70.59%
3M total return	-70.59%
3Y price change	-99.9%
3Y return CAGR	-90.11%
3Y total return	-99.9%
50-day SMA	$2.25
50-day SMA vs 200-day SMA	50under200
52-week high	$47.28
52-week high date	2025-10-31
52-week low	$0.90
52-week low date	2026-10-26
5Y price change	-100%
5Y return CAGR	-86.99%
5Y total return	-100%
6M price change	-80.04%
6M total return	-80.04%
All-time high	$533,353.97
All-time high date	2019-07-25
All-time low	$0.90
All-time low date	2026-10-26
Average true range (ATR)	$0.23
Average volume	87.4K
Beta (1Y)	3.69
Beta (2Y)	2.17
Beta (5Y)	0.64
Change from 52-week high	-97.69%
Change from 52-week low	21.11%
Change from all-time high	-100%
Change from all-time low	22.21%
Change from open	1.87%
Day's gap	3.88%
Dollar volume	$69,813
High price	$1.10
Low price	$1.06
Monthly RSI	22.97
Open price	$1.07
Position in 52-week range	75%
Premarket change	0.97%
Premarket close	$1.03
Premarket price	$1.04
Premarket volume	3.9K
Previous close	$1.03
Price vs 150-day SMA	-76.04%
Price vs 20-day SMA	-15.78%
Price vs 200-day SMA	-80.46%
Price vs 50-day SMA	-51.09%
Relative volume	0.73
RSI	32.21
Sharpe ratio	-1.56
Sharpe ratio (3Y)	-0.68
Sharpe ratio (5Y)	-0.76
Sortino ratio	-2.29
Sortino ratio (3Y)	-1.21
Sortino ratio (5Y)	-1.26
Volume	64K
Weekly RSI	27.55
YTD price change	-85.87%
YTD total return	-85.87%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	586.4K
Float percentage	89.51%
Shares change (QoQ)	0%
Shares change (YoY)	319.16%
Shares held by insiders	10.49%
Shares held by institutions	1.19%
Shares outstanding	655.2K
Short % of float	25.64%
Short % of shares	22.95%
Short ratio	0 days

Deeper analysis on DCOY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DCOY report

Is a complete DCOY research report available?

No complete published report is available for Decoy Therapeutics Inc. (DCOY) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Decoy Therapeutics Inc. (DCOY)

Price

Financial snapshot

Fair-value bridge

Latest news · DCOY

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DCOY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DCOY

Frequently asked questions